A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Sitravatinib

Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

DRUG

Tislelizumab

Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody

DRUG

Nab-paclitaxel

Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin

Trial Locations (1)

Fudan University Shanghai Cancer, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER